CNBX: CNBX Pharmaceuticals Inc. Stock

by  •  • Comments Off on CNBX: CNBX Pharmaceuticals Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 0.25
Enterprise Value ($M) 1.56
Book Value ($M) -2.51
Book Value / Share -0.08
Price / Book -0.10
NCAV ($M) -2.51
NCAV / Share -0.08
Price / NCAV -0.10

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -1.42
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.01
Current Ratio 0.01

Balance Sheet (mrq) ($M)
Current Assets 0.02
Assets 0.02
Liabilities 2.54
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.13
Operating Income -0.58
Net Income -0.70
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -0.24
Cash from Investing 0.11
Cash from Financing 0.03

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A 3i, LP 9.90 0.62

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-01-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-11-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION
2024-07-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SE
2024-04-16 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024 ☐ TRANSITION REPORT PURSUANT

(click for more detail)

Similar Companies
CLYYF – Celyad Oncology SA CMRA – Comera Life Sciences Holdings, Inc.
CMVLF – Cellectis S.A. CNGT – Cannagistics, Inc.
CPMD – CannaPharmaRX, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Cannabics Pharmaceuticals